Table 4.

Multivariate association between donor RTL and HCT outcome in the combined cohorts comparing long to short RTL (using the 25^th percentile as a cut-off point).

Outcome	N event/N total	HR*	95% CI	p-value
OS	564/1077	0.99	0.81-1.20	0.91
DFS	577/1072	0.99	0.82-1.21	0.95
TRM	265/1072	1.01	0.76-1.34	0.95
Relapse	312/1072	0.99	0.76-1.29	0.59
aGVHD II-IV	472/1067	0.89	0.72-1.11	0.30
aGVHD III-IV	168/1080	1.06	0.74-1.52	0.75
cGVHD	582/1032	0.97	0.79-1.18	0.75
Neutrophil engraftment	1040/1065	1.13	0.97-1.31	0.11

^*Hazard ratio; models are adjusted for the following covariates:

OS: cytogenetics, donor age, recipient age, use of TBI; stratified by graft type

DFS: cytogenetics, donor age, recipient age, disease status, interval from diagnosis to transplant; stratified by graft type

TRM: cytogenetics, donor age, recipient age, graft type and use of TBI; stratified by graft type

Relapse: cytogenetics, disease status, interval from diagnosis to transplant, donor age

aGVHD II-IV: ATG, use of alemtuzumab, recipient-donor sex match; stratified by permissive mismatches and year of transplant, donor age

aGVHD III-IV: ATG, graft type and recipient-donor sex match; stratified by TCE match, donor age

cGVHD: ATG, use of alemtuzumab, conditioning regimen, graft type and year of transplant, donor age

Neutrophil engraftment: ABO match, donor age, GvHD prophylaxis; stratified on graft type, and conditioning regimen